StockIQpro
NASDAQ:BBOT

BridgeBio Oncology Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

BridgeBio Oncology Therapeutics, Inc. reported net income of −$134.0M in fiscal 2025. Free cash flow was −$114.5M, and the diluted share count rose 241276.2%.Summary generated from BridgeBio Oncology Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 5, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−115.3%
Debt / equityn/a
Free cash flow−$114.5M
FCF marginn/a
Share count change+241276.2%

Financials

Fiscal years, $M
Item202320242025
Revenuen/an/an/a
Operating income−0−81−146
Net income−0−74−134
Free cash flown/a−55−115

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations